News

Latest news

Hide mandatory notifications of trade
  • Mandatory Notification of Trade - Cecilie Grue

    Financial .2016

    (Oslo, Norway, 27 September 2016) Reference is made to the announcement on 14 September 2016 by Bionor Pharma ASA ("Bionor" or the "Company", ticker "BIONOR") regarding the primary insider notification from certain primary insiders of the Company that have received Subscription Rights in the Rights Issue.

  • Mandatory Notification of Trade - Sommerfelt

    Financial .2016

    (Oslo, Norway, 26 September 2016) Reference is made to the announcement on 14 September 2016 by Bionor Pharma ASA ("Bionor" or the "Company", ticker "BIONOR") regarding the primary insider notification from certain primary insiders of the Company that have received Subscription Rights in the Rights Issue.

  • Mandatory Notification of Trade - Flåten

    Financial .2016

    (Oslo, Norway, 26 September 2016) Reference is made to the announcement on 14 September 2016 by Bionor Pharma ASA ("Bionor" or the "Company", ticker "BIONOR") regarding the primary insider notification from certain primary insiders of the Company that have received Subscription Rights in the Rights Issue.

  • Mandatory Notification of Trade - Hjelmaas

    Financial .2016

    (Oslo, Norway, 26 September 2016) Reference is made to the announcement on 14 September 2016 regarding the Rights Offering in Bionor Pharma ASA (the “Company”).

  • Poster presentation at the 18th Institute of Human Virology Annual Conference

    Scientific .2016
  • Mandatory Notification of Trade

    Financial .2016

    Lars Høie has on 19 September 2016 disposed of 20,000,000 subscription rights obtained in connection with the rights offering in Bionor Pharma ASA (the "Company").

  • Mandatory Notification of Trade

    Financial .2016

    Lars Høie has on 16 September 2016 sold 25,000,000 shares in Bionor Pharma ASA (the "Company") at a price of NOK 0.25 per share.

  • Bionor Pharma – Share capital increase registered

    Financial .2016

    (Oslo, Norway, 15 September 2016) Reference is made to the stock exchange announcement by Bionor Pharma ASA ("Bionor" or the "Company", ticker "BIONOR") published on 9 September 2016 regarding the extraordinary general meeting in the Company approving inter alia a share capital reduction and a share capital increase through a private placement of 525,000,000 new shares each at a par value of NOK 0.10 (the "Private Placement").

  • Primary insider notification regarding Subscription Rights in the Rights Issue

    Financial .2016

    (Oslo, Norway, 14 September 2016) Reference is made to the announcement on 14 September 2016 by Bionor Pharma ASA ("Bionor"or the"Company",ticker "BIONOR") regarding inter alia the rights issue of 525,000,000 new shares in the Company at a subscription price of NOK 0.10 per share (the"Rights Issue") to shareholders in the Company as per the end of 9 September 2016 who shall have preferential rights to subscribe for new shares in the Company, provided such are not resident in a jurisdiction where such offering would be unlawful, or would (in jurisdictions other than Norway) require any prospectus filing, registration or similar action (the"Eligible Shareholders").

  • Bionor Pharma – Approval and publication of prospectus, commencement of subscription period and listing of new shares

    Financial .2016

    (Oslo, Norway, 14 September 2016) Reference is made to the stock exchange announcement by Bionor Pharma ASA ("Bionor" or the "Company", ticker "BIONOR") dated 9 September 2016 regarding the completion of the Company’s extraordinary general meeting ("EGM").